CTOs on the Move


 
Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vysis.com
  • 3100 Woodcreek Dr
    Downers Grove, IL USA 60515
  • Phone: 630.271.7000

Executives

Name Title Contact Details

Similar Companies

Neurotrack

Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.

Infinity BiologiX

RUCDR Infinite Biologics Becomes Infinity BiologiX IBX will continue to advance RUCDR`s founding mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. IBX will continue to collaborate with – and provide services to – researchers in both the public and private sectors globally, including innovative and market-disrupting sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas.

Arnold A Welu Dental Laboratory

Arnold A Welu Dental Laboratory, Inc is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nonlethal Technologies

Nonlethal Technologies, Inc is a Homer City, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kadmon

Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.